Pulmonary Vascular Disease News

Techdow USA announced the FDA approval of its generic enoxaparin sodium for marketing in the U.S.

Inhaled treprostinil is used to treat pulmonary hypertension with interstitial lung disease, and a study recently found that higher doses led to better clinical outcomes than a lower dose or placebo.

LivaNova announced it received FDA 510(k) clearance for its heart-lung machine and initiated the commercial launch of the machine in the U.S.

NEW ORLEANS — Compared with other treatment options and historical data, large-bore mechanical thrombectomy conferred reduced risk for in-hospital adverse clinical outcomes in high-risk patients with pulmonary embolism, data showed.

NEW ORLEANS — Sotatercept, a novel activin signaling inhibitor, reduced risk for death and clinical worsening by 84% in patients with pulmonary arterial hypertension compared with placebo, according to results of the STELLAR trial.

Among patients hospitalized with COVID-19, men were more likely than women to have CV complications, but the difference was not explained by lower rates of past CVD in women, researchers reported in BMJ Medicine.

Chest sensors that measured heart rate and accelerometry enabled patients with pulmonary artery hypertension to undergo 6-minute walk tests remotely with similar data as those collected in clinic, according to study results in CHEST.

Evidence suggests that high-risk patients with pulmonary embolism can benefit from surgical management, according to a scientific statement issued by the American Heart Association.

Patients with venous thromboembolism treated with anticoagulants for more than 3 months had a lower risk for major adverse cardiovascular events, according to a study published in CHEST.

Healthy women who delayed their normal bedtime by 1.5 hours showed endothelial dysfunction, which increases risk for cardiovascular disease, according to a study published in Annals of the American Thoracic Society.